agxАндрология и генитальная хирургияAndrology and Genital Surgery2070-97812412-8902MedINK Publishing House LLC10.63769/2070-9781-2025-25-4-50-58agx-832Research ArticleОРИГИНАЛЬНАЯ СТАТЬЯORIGINAL REPORTРезультаты лечения и активного наблюдения при локализованном раке предстательной железы на территории Самарской области.Results Of Treatment And Active Monitoring Of Patients With Localized Prostate Cancer In The Samara Regionhttps://orcid.org/0000-0001-5385-7049АндрееваР. Д.AndreevaR. D.

Рамиля Дамировна Андреева, ассистент

кафедра урологии

443099; ул. Чапаевская, 89; Самара

AuthorID: 1061971

Ramilya D. Andreeva, assistant

Department of Urology

443099; Chapaevskaya str., 89; Samara

AuthorID: 1061971

r.d.andreeva@samsmu.ruhttps://orcid.org/0000-0003-4452-8547НизамоваР. С.NizamovaR. S.

Румия Сахабовна Низамова, заведующая кафедрой, доктор медицинских наук, профессор

кафедра урологии

443099; ул. Чапаевская, 89; Самара

Тел.: +79276035706

AuthorID: 395334

Rumiya S. Nizamova, Head of the Department, MD, Professor

Department of Urology

443099; Chapaevskaya str., 89; Samara

Tel.: +79276035706

AuthorID: 395334

nizamovars@ya.ruФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России; Самарский областной клинический онкологический диспансерРоссияSamara State Medical University, Ministry of Health of Russia;Samara Regional Clinical Oncological DispensaryRussian FederationФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России; Самарский областной клинический онкологический диспансерРоссияSamara State Medical University, Ministry of Health of RussiaRussian Federation2025270220262545058Copyright © Андреева Р.Д., Низамова Р.С., 20262026Андреева Р.Д., Низамова Р.С.Andreeva R.D., Nizamova R.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://agx.elpub.ru/jour/article/view/832

   В статье представлены результаты исследования безрецидивной выживаемости у пациентов локализованным раком предстательной железы в Самарской области с фокусом на сравнении эффективности радикального лечения и активного наблюдения в зависимости от группы онкологического риска прогрессии. Анализ данных показал статистически значимые различия в показателях безрецидивной выживаемости. Результаты лечения подчеркивают критическую важность стратификации пациентов по группам риска для принятия обоснованных клинических решений в выборе тактики лечения больных локализованным раком предстательной железы.

   The article presents the results of a study of relapse-free survival in patients with localized prostate cancer in the Samara region, focusing on comparing the effectiveness of radical treatment and active surveillance, depending on the cancer progression risk group. The data analysis showed statistically significant differences in relapse-free survival rates. The treatment results highlight the critical importance of risk group stratification for making informed clinical decisions in the treatment of patients with localized prostate cancer.

рак предстательной железыгруппа рискабезрецидивная выживаемостьлокализованный рак простатыprostate cancerrisk grouprelapse-free survivallocalized prostate cancerИсследование проведено без спонсорской поддержкиThe study was performed without external fundingReferencesSung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660.Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660.Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. doi: 10.3322/caac.21830. PMID: 38230766.Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. doi: 10.3322/caac.21830. PMID: 38230766.Al Hussein Al Awamlh B, Wallis CJD, Penson DF, Huang LC, Zhao Z, Conwill R, Talwar R, Morgans AK, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, O’Neil BB, Koyama T, Hoffman KE, Barocas DA. Functional Outcomes After Localized Prostate Cancer Treatment. JAMA. 2024 Jan 23;331(4):302-317. doi: 10.1001/jama.2023.26491. PMID: 38261043; PMCID: PMC10807259.Al Hussein Al Awamlh B, Wallis CJD, Penson DF, Huang LC, Zhao Z, Conwill R, Talwar R, Morgans AK, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, O’Neil BB, Koyama T, Hoffman KE, Barocas DA. Functional Outcomes After Localized Prostate Cancer Treatment. JAMA. 2024 Jan 23;331(4):302-317. doi: 10.1001/jama.2023.26491. PMID: 38261043; PMCID: PMC10807259.Klotz L. Active Surveillance for Prostate Cancer : Overview and Update. Curr Treat Options Oncol. 2013;14(2):97-108. doi: 10.1007/s11864-013-0225-9.Klotz L. Active Surveillance for Prostate Cancer : Overview and Update. Curr Treat Options Oncol. 2013;14(2):97-108. doi: 10.1007/s11864-013-0225-9.Marisov LV, Vinarov AZ. [Diagnosis and treatment of incidental prostate cancer]. Urologiia. 2014 May-Jun;(3):82-5. Russian. PMID: 25211935.Marisov LV, Vinarov AZ. [Diagnosis and treatment of incidental prostate cancer]. Urologiia. 2014 May-Jun;(3):82-5. Russian. PMID: 25211935.Чиненов Д.В., Шпоть Е.В., Чернов Я.Н., и др. Малоинвазивные методы лечения локализованного рака предстательной железы // Урология. - 2019. - № 6. - C. 156-165. doi: 10.18565/urology.2019.6.156-164Chinyonov D.V., Shpot E.V., Chernov Ya.N., et al. Minimally invasive methods of treating localized prostate cancer // Urology. - 2019. - No. 6. - Pp. 156-165. (In Russ.) doi: 10.18565/urology.2019.6.156-164Guillaumier S, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol. 2018;74(4):422-429. doi: 10.1016/j.eururo.2018.06.006.Guillaumier S, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol. 2018;74(4):422-429. doi: 10.1016/j.eururo.2018.06.006.Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-974. doi: 10.1016/j.ijrobp.2006.04.029.Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-974. doi: 10.1016/j.ijrobp.2006.04.029.Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540-545. doi: 10.1016/j.juro.2006.10.097.Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540-545. doi: 10.1016/j.juro.2006.10.097.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer. Version 4. 2024. National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer. Version 4. 2024. National Comprehensive Cancer Network.Cornford P, van den Bergh RCN, Briers E, et all. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024 Aug;86(2):148-163. doi: 10.1016/j.eururo.2024.03.027. Epub 2024 Apr 13. PMID: 38614820.Cornford P, van den Bergh RCN, Briers E, et all. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024 Aug;86(2):148-163. doi: 10.1016/j.eururo.2024.03.027. Epub 2024 Apr 13. PMID: 38614820.Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.N Engl J Med. 2016;375(15):1415-1424. doi: 10.1056/NEJMoa1606220.Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.N Engl J Med. 2016;375(15):1415-1424. doi: 10.1056/NEJMoa1606220.Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388(17):1547-1558. doi: 10.1056/NEJMoa2214122.Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388(17):1547-1558. doi: 10.1056/NEJMoa2214122.Bill-Axelson A, Holmberg L, Garmo H, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018;379(24):2319-2329. doi: 10.1056/NEJMoa180780.Bill-Axelson A, Holmberg L, Garmo H, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018;379(24):2319-2329. doi: 10.1056/NEJMoa180780.Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377(2):132-142. doi:10.1056/NEJMoa1615869.Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017;377(2):132-142. doi:10.1056/NEJMoa1615869.Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107-118. doi: 10.1056/NEJMoa1012348.Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107-118. doi: 10.1056/NEJMoa1012348.Tilki et al.: Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. J Clin Oncol. 2020;38(26):3024-3031.Tilki et al.: Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. J Clin Oncol. 2020;38(26):3024-3031.Bria et al.: Addition of androgen deprivation therapy to radical radiotherapy in prostate cancer: a meta-analysis of randomized trials. Ann Oncol. 2016;27(6):1096-104.Bria et al.: Addition of androgen deprivation therapy to radical radiotherapy in prostate cancer: a meta-analysis of randomized trials. Ann Oncol. 2016;27(6):1096-104.Bolla M, Maingon P, Carrie C, et al. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. J Clin Oncol. 2016;34(15):1748-1756. doi: 10.1200/JCO.2015.64.8055.Bolla M, Maingon P, Carrie C, et al. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. J Clin Oncol. 2016;34(15):1748-1756. doi: 10.1200/JCO.2015.64.8055.Morris WJ, Tyldesley S, Rodda S, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026.Morris WJ, Tyldesley S, Rodda S, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026.Bokhorst LP, Valdagni R, Rannikko A, et al. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. Eur Urol. 2016;70(6):954-960. doi: 10.1016/j.eururo.2016.06.007.Bokhorst LP, Valdagni R, Rannikko A, et al. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. Eur Urol. 2016;70(6):954-960. doi: 10.1016/j.eururo.2016.06.007.Носов Д.А., Волкова М.И., Гладков О.А. и соавт. Рак предстательной железы. Практические рекомендации RUSSCO, часть 1.2. Злокачественные опухоли 2024;14(3s2):242–269.Nosov D.A., Volkova M.I., Gladkov O.A., et al. Prostate Cancer. RUSSCO Practical Guidelines, Part 1.2. Malignant Tumors 2024;14(3s2):242–269. (In Russ.)Tohi Y, Kato T, Sugimoto M. Aggressive Prostate Cancer in Patients Treated with Active Surveillance. Cancers (Basel). 2023 Aug 25;15(17):4270. doi: 10.3390/cancers15174270. PMID: 37686546; PMCID: PMC10486407.Tohi Y, Kato T, Sugimoto M. Aggressive Prostate Cancer in Patients Treated with Active Surveillance. Cancers (Basel). 2023 Aug 25;15(17):4270. doi: 10.3390/cancers15174270. PMID: 37686546; PMCID: PMC10486407.Ciccone G, De Luca S, Oderda M, et all. START Collaborative Group. Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer. JAMA Netw Open. 2023 Oct 2;6(10):e2338039. doi: 10.1001/jamanetworkopen.2023.38039. PMID: 37847502; PMCID: PMC10582795.Ciccone G, De Luca S, Oderda M, et all. START Collaborative Group. Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer. JAMA Netw Open. 2023 Oct 2;6(10):e2338039. doi: 10.1001/jamanetworkopen.2023.38039. PMID: 37847502; PMCID: PMC10582795.Hayashi, M. Long-term outcomes and prognosis of transrectal high-intensity focused ultrasound therapy for patients with localized prostate cancer – therapy after recurrence and predictive factors / M. Hayashi, T. Hayashi, T. Oka [et al.] // Open Journal of Urology. – 2017. – Vol. 07 (06). – 16 p. Article ID:77326.Hayashi, M. Long-term outcomes and prognosis of transrectal high-intensity focused ultrasound therapy for patients with localized prostate cancer – therapy after recurrence and predictive factors / M. Hayashi, T. Hayashi, T. Oka [et al.] // Open Journal of Urology. – 2017. – Vol. 07 (06). – 16 p. Article ID:77326.

The authors declare that there are no conflicts of interest present.